Voyager Therapeutics, Inc.
VYGR · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $45 | $44 | $75 | $71 |
| Short-Term Investments | $164 | $172 | $161 | $195 |
| Receivables | $4 | $3 | $2 | $4 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Curr. Assets | $7 | $10 | $7 | $6 |
| Total Curr. Assets | $220 | $228 | $245 | $277 |
| Property Plant & Equip (Net) | $43 | $45 | $46 | $48 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $20 | $46 | $59 | $66 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $6 | $3 | $3 | $3 |
| Total NC Assets | $69 | $94 | $108 | $116 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $288 | $322 | $353 | $393 |
| Liabilities | – | – | – | – |
| Payables | $2 | $2 | $3 | $4 |
| Short-Term Debt | $8 | $8 | $7 | $7 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $0 | $0 | $21 | $24 |
| Other Curr. Liab. | $26 | $33 | $9 | $14 |
| Total Curr. Liab. | $35 | $42 | $40 | $50 |
| LT Debt | $31 | $33 | $35 | $36 |
| Deferred Rev, NC | $0 | $0 | $5 | $6 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $2 | $4 | $1 | $1 |
| Total NC Liab. | $33 | $36 | $40 | $44 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $38 | $40 | $42 | $44 |
| Total Liabilities | $68 | $78 | $81 | $93 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | -$418 | -$391 | -$357 | -$326 |
| AOCI | $0 | -$0 | -$0 | -$0 |
| Other Equity | $638 | $635 | $630 | $626 |
| Total Equity | $220 | $244 | $273 | $300 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $288 | $322 | $353 | $393 |
| Net Debt | -$7 | -$4 | -$33 | -$28 |